1. Market Research
  2. > Business Services
  3. > Research and Development Market Trends
  4. > Pergamum AB - Product Pipeline Review - 2015

Pergamum AB - Product Pipeline Review - 2015

  • October 2015
  • -
  • Global Markets Direct
  • -
  • 23 pages

Pergamum AB - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Pergamum AB - Product Pipeline Review - 2015’, provides an overview of the Pergamum AB’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pergamum AB’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Pergamum AB including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pergamum AB’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pergamum AB’s pipeline products

Reasons to buy

- Evaluate Pergamum AB’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pergamum AB in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pergamum AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pergamum AB and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pergamum AB
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Pergamum AB and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Pergamum AB - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Pergamum AB Snapshot 4
Pergamum AB Overview 4
Key Information 4
Key Facts 4
Pergamum AB - Research and Development Overview 5
Key Therapeutic Areas 5
Pergamum AB - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pergamum AB - Pipeline Products Glance 9
Pergamum AB - Clinical Stage Pipeline Products 9
Phase II Products/Combination Treatment Modalities 9
Phase I Products/Combination Treatment Modalities 10
Pergamum AB - Early Stage Pipeline Products 11
Discovery Products/Combination Treatment Modalities 11
Pergamum AB - Drug Profiles 12
DPK-060 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
PXL-01 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
LL-37 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
PXL-181 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Pergamum AB - Pipeline Analysis 16
Pergamum AB - Pipeline Products by Route of Administration 16
Pergamum AB - Pipeline Products by Molecule Type 17
Pergamum AB - Recent Pipeline Updates 18
Pergamum AB - Dormant Projects 20
Pergamum AB - Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
Coverage 22
Secondary Research 22
Primary Research 22
Expert Panel Validation 22
Contact Us 22
Disclaimer 23

List of Tables
Pergamum AB, Key Information 4
Pergamum AB, Key Facts 4
Pergamum AB - Pipeline by Indication, 2015 6
Pergamum AB - Pipeline by Stage of Development, 2015 7
Pergamum AB - Monotherapy Products in Pipeline, 2015 8
Pergamum AB - Phase II, 2015 9
Pergamum AB - Phase I, 2015 10
Pergamum AB - Discovery, 2015 11
Pergamum AB - Pipeline by Route of Administration, 2015 16
Pergamum AB - Pipeline by Molecule Type, 2015 17
Pergamum AB - Recent Pipeline Updates, 2015 18
Pergamum AB - Dormant Developmental Projects,2015 20

List of Figures
Pergamum AB - Pipeline by Top 10 Indication, 2015 6
Pergamum AB - Pipeline by Stage of Development, 2015 7
Pergamum AB - Monotherapy Products in Pipeline, 2015 8
Pergamum AB - Pipeline by Top 10 Route of Administration, 2015 16
Pergamum AB - Pipeline by Top 10 Molecule Type, 2015 17

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Integrin Alpha 7 (ITGA7) - Pipeline Review, H2 2016’, provides in depth analysis on Integrin Alpha 7 (ITGA7) ...

Pulmonary Fibrosis - Pipeline Review, H2 2016

Pulmonary Fibrosis - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Pulmonary Fibrosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Pulmonary Fibrosis - Pipeline Review, H2 2016’, provides an overview of the Pulmonary Fibrosis pipeline landscape. ...

Cognitive Impairment - Pipeline Review, H2 2016

Cognitive Impairment - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Cognitive Impairment - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Cognitive Impairment - Pipeline Review, H2 2016’, provides an overview of the Cognitive Impairment pipeline landscape. ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.